Spots Global Cancer Trial Database for Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis

Official Title: Phase I Dose Escalation Trial of Hypofractionated Radiosurgery for Large Brain Metastasis

Study ID: NCT01705548

Conditions

Metastatic Malignant Neoplasm to Brain

Unspecified Adult Solid Tumor, Protocol Specific

Interventions

Hypofractionated Radiosurgery

Study Description

Brief Summary: This phase I trial studies the side effects and best dose of hypofractionated radiosurgery in treating patients with large brain metastasis. Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. Giving fractionated stereotactic radiosurgery may kill more tumor cells.

Detailed Description: PRIMARY OBJECTIVE: To demonstrate the safety and feasibility of treating brain metastases or resection cavities greater than 3 cm with hypofractionated radiosurgery and to determine the maximum-tolerated radiation dose for hypofractionated radiosurgery (HR) delivered in 5 fractions, 2-3 fractions per week. OUTLINE: This is a dose-escalation study. Patients undergo hypofractionated stereotactic radiosurgery 2-3 times weekly (5 fractions total) for 2-3 weeks. After completion of study treatment, patients are followed up at 1 month and then every 3 months thereafter.